RBB Bancorp announced a net income of $12.6 million for Q3 2026, up from $10.1 million in Q2, driven by higher net interest income and reduced nonperforming assets. The bank's net interest margin improved to 3.16%, supported by strong retail deposit growth and a partial redemption of subordinated notes. Nonperforming assets decreased by 11.3%, reflecting improved credit quality, while loan growth remained robust with a 10.8% annualized increase. The company declared a quarterly cash dividend of $0.16 per share, signaling confidence in its financial position and growth outlook.
RBB Bancorp's Q3 2026 earnings and dividend announcement provide context for financial sector activity. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 20, 2026 02:12 WIB: out of 142 priced US Financials stocks, 28 rose and 113 fell. Wells Fargo & Co traded at USD 81.75 with a 1-day change of -2.53%, NatWest Group plc at USD 17.07 down 2.51%, and Charles Schwab Corporation at USD 89.73 down 2.42%.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
